Interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients

AIDS Research and Human Retroviruses

Volumn 19, Issue 3, 2003, Pages 187-188

  Nóñez, Marina ^a   González Requena, Daniel ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEVIRAPINE; VIRUS ANTIBODY; AMINOTRANSFERASE; INDINAVIR; NUCLEOSIDE DERIVATIVE;

ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; VIROLOGY; AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; HUMAN CELL; LIVER CIRRHOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; PRIORITY JOURNAL; RISK FACTOR;

ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ANTIBODIES, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER DISEASES; NEVIRAPINE;

EID: 0037349981     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203763315687     Document Type: Article

References (10)

1. Saves M, Vandentorren S, Daucourt V, et al.: Severe hepatic cytolysis: Incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. AIDS 1999;13:F115-F121.
2. Sulkowski M, Thomas D, Chaisson R, and Moore R: Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
3. Den Brinker M, Wit F, Wertheim-van Dillen P, et al.: Hepatitis B and C virus coinfection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14: 2895-2902.
4. Saves M, Raffi F, Clevenbergh P, et al.: Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in HIV-infected patients. Antimicrob Agents Chemother 2000;44: 3451-3455.
5. Núñez M, Lana R, Mendoza J, Martín-Carbonero L, and Soriano V: Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquit Immune Defic Syndr 2001; 27:426-431.
6. Wit F, Weverling G, Weel J, Jurriaans S, and Lange J: Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. Clin Infect Dis 2002;186:23-31.
7. Gonzalez D, Nuñez M, Jimeñez I, and Soriano V: Liver toxicity caused by nevirapine. AIDS 2002;16:290-291.
8. Rolf P, Van Heeswijk O, Hoetelmans R, et al.: Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 1998;713:395-399.
9. Malavaud B, Dinh B, Bonnet E, Izopet J, Payen J, and Marchou B: Increased incidence of indinavir nephrolitiasis in patients with hepatitis B or C virus infection. Antiviral Ther 2000;5:3-5.
10. Maat M, Huitema A, Mulder J, Meenhorst P, van Gorp E, and Beijnen J: Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals [Abstract TuPeB4567]. In: Abstracts of the XIV International AIDS Conference. Barcelona, Spain, July 2002.